In a small cohort of patients with AML, a correlation has been reported between high CD157 expression levels and the adverse prognosis group of patients according to the European Leukemia Net (ELN) classification-2017 [74], but not with NPM1 and FLT3-ITD mutational status [73]. This evidence concerns the gene BST1 and acute myeloid leukemia.